<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932215</url>
  </required_header>
  <id_info>
    <org_study_id>7242</org_study_id>
    <nct_id>NCT02932215</nct_id>
  </id_info>
  <brief_title>Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder</brief_title>
  <official_title>Pilot Study: Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 10 week, open-label, prospective study, involving 10 volunteer participants with&#xD;
      cannabis use disorder to test the feasibility and safety of using lorcaserin in addition to&#xD;
      the feasibility, likability, and utility of a mobile sensor device in cannabis users. The&#xD;
      study will be entirely outpatient. Upon study entry, participants will begin clinic visits at&#xD;
      the Substance Treatment and Research Service (STARS) clinic. All consented participants will&#xD;
      receive a Fitbit Charge HR device in week 1 to wear for the entire study and receive&#xD;
      lorcaserin beginning in week 2 for a total of 8 weeks (weeks 2-9). At the beginning of week&#xD;
      10 following discontinuation of lorcaserin, the participants will continue to wear the Fitbit&#xD;
      Charge HR device for this final week following completion of the medication trial. All&#xD;
      participants will visit the clinic twice weekly to provide urine toxicology on THC, report on&#xD;
      adverse events, complete additional assessments (outlined below), and upload de-identified&#xD;
      data from the Fitbit Charge HR device to the secure encrypted Fitabase database. Study&#xD;
      assessments will be collected at baseline, throughout the study, and 1 week following&#xD;
      medication discontinuation. All participants will also receive medical management, a&#xD;
      medication adherence focused psychosocial intervention that facilitates compliance with study&#xD;
      medication and other study procedures, including adherence to wearing the Fitbit Charge HR&#xD;
      device, and promotes abstinence from cannabis and other substances. Progressive voucher&#xD;
      incentives will be provided for compliance with visit attendance and study procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design Overview: This is a 10 week, open-label, prospective study, involving 10 volunteer&#xD;
      participants with cannabis use disorder to test the feasibility and safety of using&#xD;
      lorcaserin in addition to the feasibility, likability, and utility of a mobile sensor device&#xD;
      in cannabis users. The study will be entirely outpatient Upon study entry, participants will&#xD;
      begin clinic visits at the Substance Treatment and Research Service (STARS) clinic. All&#xD;
      consented participants will receive a Fitbit charge HR mobile device in week 1 to wear for&#xD;
      the entire study and receive lorcaserin beginning in week 2 for a total of 8 weeks (weeks&#xD;
      2-9). At the beginning of week 10 following discontinuation of lorcaserin, the participants&#xD;
      will continue to wear the device for this final week following completion of the medication&#xD;
      trial. All participants will visit the clinic twice weekly to provide urine toxicology on&#xD;
      THC, report on adverse events, complete additional assessments (outlined below), and upload&#xD;
      de-identified data from the device to a secure encrypted database. Study assessments will be&#xD;
      collected at baseline, throughout the study, and 1 week following medication discontinuation.&#xD;
      All participants will also receive medical management, a medication adherence focused&#xD;
      psychosocial intervention that facilitates compliance with study medication and other study&#xD;
      procedures, including adherence to wearing the device, and promotes abstinence from cannabis&#xD;
      and other substances. Progressive voucher incentives will be provided for compliance with&#xD;
      visit attendance and study procedures.&#xD;
&#xD;
      The specific aims of the project are:&#xD;
&#xD;
        1. To determine whether lorcaserin is associated with a reduction from baseline in cannabis&#xD;
           use in individuals with cannabis use disorder seeking treatment.&#xD;
&#xD;
        2. To determine the tolerability of lorcaserin in this population.&#xD;
&#xD;
        3. To evaluate the feasibility and likability of incorporating a mobile health sensor&#xD;
           device in a treatment study for cannabis use disorder.&#xD;
&#xD;
      The primary outcome measures are:&#xD;
&#xD;
        1. Lorcaserin will significantly reduce cannabis use during the study period as measured by&#xD;
           self-report (Timeline Followback) and creatinine-normalized quantitative THC urine&#xD;
           levels.&#xD;
&#xD;
        2. Lorcaserin will be well tolerated in participants with cannabis use disorder as measured&#xD;
           by the proportion of participants completing the study, adherence to medication, and the&#xD;
           proportion of participants experiencing adverse events.&#xD;
&#xD;
        3. Participants will find it feasible and likeable to utilize the Fitbit Charge HRTM in the&#xD;
           study as measured by selfreport assessment of liking and adherence to wearing the device&#xD;
&#xD;
      Secondary aims include:&#xD;
&#xD;
        1. To evaluate the effect of medication treatment for cannabis use disorder on activity,&#xD;
           sleep, stress, and quality of life as measured with a mobile sensor device and&#xD;
           self-report assessments in individuals with cannabis use disorder.&#xD;
&#xD;
        2. To evaluate the correlation between summarized Fitbit Charge HR health sensor measures&#xD;
           and self-report assessments of sleep, stress, and quality of life in addition to&#xD;
           participants' use of cannabis and cannabis withdrawal at baseline, during, and after a&#xD;
           treatment trial.&#xD;
&#xD;
      The secondary outcome measures include:&#xD;
&#xD;
        1. Medication treatment will increase positive health behaviors including activity and&#xD;
           improve sleep (increase total sleep time and percentage deep sleep) in addition to&#xD;
           decreasing stress and improving quality of life as measured by summarized daily total&#xD;
           steps, sleep duration and quality, and summarized stress score measured with device in&#xD;
           conjunction with improvement in the Pittsburgh Sleep Quality Inventory (PSQI), decreased&#xD;
           Perceived Stress Scale score (PSS), and improvement on Quality of Life, Enjoyment, and&#xD;
           Satisfaction Questionnaire (QLESQ), as compared to baseline. Negative health behaviors&#xD;
           (poor sleep, decreased activity, increased stress) will be highest within subjects&#xD;
           before starting treatment and with initial abstinence from cannabis when withdrawal&#xD;
           symptoms are most prominent. Positive health behaviors will increase during treatment&#xD;
           within subject, and particularly towards the second half of treatment as reduction in&#xD;
           cannabis use or abstinence is sustained.&#xD;
&#xD;
        2. The device measures and self-report measures will directly correlate, as expected; ie:&#xD;
           increased sleep and increased % of deep sleep will correlate with higher PSQI scores.&#xD;
           When participants are using baseline levels of cannabis or are in cannabis withdrawal,&#xD;
           they will have device measures consistent with negative health behaviors (poor sleep,&#xD;
           decreased activity, increased stress). When they reduce cannabis use or achieve&#xD;
           abstinence for a sustained period (any 14 days), an association with positive health&#xD;
           behaviors as measured by the mobile device (adequate sleep, adequate activity, decreased&#xD;
           stress) will increase.&#xD;
&#xD;
      The objective of the pilot is to obtain preliminary data on cannabis use patterns,&#xD;
      tolerability of this medication, and sleep, quality of life and activity patterns in&#xD;
      individuals with cannabis use disorder before conducting a larger trial with lorcaserin and&#xD;
      to inform future applications of mobile sensors to cannabis use disorder treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">January 17, 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cannabis use</measure>
    <time_frame>weeks 1-10</time_frame>
    <description>urine toxicology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to device</measure>
    <time_frame>weeks 1-10</time_frame>
    <description>days device is worn</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of implementing mobile health device in treatment trial for CUD</measure>
    <time_frame>assessed once at 10weeks (end of study)</time_frame>
    <description>5 question self-report on likability of device; eg: Question 1: did you like wearing the mobile sensor device to track your progress during treatment? Yes or No; Question 2: Would you continue to wear the mobile sensor device to track your behaviors? Yes or No; etc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cannabis Use</measure>
    <time_frame>weeks 1-10</time_frame>
    <description>Timeline Followback</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adherence to medication</measure>
    <time_frame>weeks 1- 8</time_frame>
    <description>number of pills taken</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive open label lorcaserin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorcaserin</intervention_name>
    <description>Open label</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>Belviq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fitbit Charge HR</intervention_name>
    <description>This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals between the ages of 18-60&#xD;
&#xD;
          -  Meets DSM-V criteria for a current cannabis use disorder&#xD;
&#xD;
          -  Seeking treatment for cannabis use disorder&#xD;
&#xD;
          -  THC-positive urine drug screen&#xD;
&#xD;
          -  Capable of giving informed consent and complying with study procedures&#xD;
&#xD;
          -  Has access to a mobile device with IOS7 or Android 4.4.2 capabilities or more recent&#xD;
             operating systems&#xD;
&#xD;
          -  Not underweight (Defined as BMI â‰¥18.5)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lifetime history of DSM-V diagnosis of schizophrenia, schizoaffective disorder, or&#xD;
             bipolar disorder&#xD;
&#xD;
          -  Current DSM-V criteria for any other psychiatric disorder supported by the MINI that&#xD;
             in the investigator's judgment is unstable, would be disrupted by the study&#xD;
             medication, or is likely to require new pharmacotherapy or psychotherapy during the&#xD;
             study period. Individuals who are currently stable on a psychotropic medication for at&#xD;
             least 3 months may be included if in the investigator's opinion the psychotropic&#xD;
             medication the patient is taking is compatible with the study medication (lorcaserin).&#xD;
&#xD;
          -  Individuals who meet DSM-V criteria for any substance use disorder other an cannabis,&#xD;
             caffeine or nicotine use disorders&#xD;
&#xD;
          -  Pregnancy, lactation, or failure to use adequate contraceptive method in female&#xD;
             patients who are currently engaging in sexual activity with men&#xD;
&#xD;
          -  Unstable medical conditions, such as AIDS, cancer, uncontrolled hypertension (blood&#xD;
             pressure &gt; 140/90), uncontrolled diabetes, pulmonary hypertension or heart disease&#xD;
&#xD;
          -  Legally mandated to participate in a substance use disorder treatment program&#xD;
&#xD;
          -  Current or recent history of significant violent orsuicidal behavior, risk for suicide&#xD;
             or homicide psychiatrist&#xD;
&#xD;
          -  Currently meets DSM-V diagnosis for an eating disorder or is underweight (defined as&#xD;
             BMI &lt;18.5)&#xD;
&#xD;
          -  Elevated liver function tests (AST and ALT &gt; 3 times the upper limit of normal) or&#xD;
             impaired renal function&#xD;
&#xD;
          -  Known history of allergy, intolerance, or hypersensitivity to lorcaserin&#xD;
&#xD;
          -  Concurrent use of migraine medications ergotamine (Cafergot, Ergomar) or&#xD;
             dihydroergotamine (Migranal), 5HT2B receptor agonists like cabergoline, or medications&#xD;
             metabolized by CYP2D6 (thioridazine, tamoxifen, metoprolol, aripiprazole, codeine,&#xD;
             etc)&#xD;
&#xD;
          -  No access to mobile device with IOS7 or Android 4.4.2 capabilities or more recent&#xD;
             operating systems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Columbia Substance Treatment and Research Service</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Christina Ann Brezing</investigator_full_name>
    <investigator_title>research psychiatrist</investigator_title>
  </responsible_party>
  <keyword>mobile health device</keyword>
  <keyword>substance abuse treatment</keyword>
  <keyword>quality of life</keyword>
  <keyword>lorcaserin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

